Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003)

Conclusions:ALD403 100mg and 300mg significantly reduced migraine days in patients with chronic migraine as measured by 75% responder rates. All doses of ALD403 significantly reduced the percentage of migraine attacks that the patients reported as severe. ALD403 was generally safe and well tolerated.Study Supported by:Alder Biopharmaceuticals Bothell, WADisclosure: Dr. Dodick has received personal compensation for activities with Allergan, Amgen, Alder, Dr Reddy’s, Merck, eNeura, Eli Lilly & Company, INSYS therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Merck, Colucid, and Zosano. Dr. Dodick has received personal compensation in an editorial capacity for Oxford University Press, Cambridge University Press, Healthlogix, UptoDate. Dr. Dodick has received royalty payments from Oxford University Press, Cambridge University Press, Web MD and UptoDate. Dr. Dodick holds stock and/or stock options in Epien Medical, Second Opinion, GBS, and Neuroassessment systems. Dr. Goadsby has received personal compensation for activities with Allergan, eNeura, Autonomic Technologies Inc, Amgen, AlderBio, Pfizer, DrReddy, Zosano, Colucid, Eli Lilly, Avanir, Gore,Heptares, Nupathe, Teva, Cipla, Ajinomoto, Akita,Wells Fargo, Ethicon,Promius. Dr. Goadsby has received personal compensation in an editorial capacity for JournalWatch Neurology and UptoDate. Dr. Goadsby has received research supporting from Amgen, eNeura, Allergan. Dr. Silberstein has...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Dodick, D., Goadsby, P., Silberstein, S., Lipton, R., Hirman, J., Smith, J. Tags: Headache: Clinical Trials and Disease Burden Source Type: research